DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02001363

UnknownPhase NA

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction

Lead sponsor

Chen Wei Ren, MD

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

90

estimated

Study population

Cardiovascular disease

Key I/E criterion

—

Primary endpoint

•Salvage index

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02001363
Org study IDS2013-099-01
Secondary IDChinaPLAGHChinaPLAGH

Timeline

Milestones

Study first posted2013-12-04estimated
Last update posted2016-02-05estimated
Study start2013-11 (month precision)
Primary completion2016-03estimated (month precision)
Study completion2016-03estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular disease

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Patients were eligible if they were 18 years or older and presented within 12 h from the onset of symptoms and signs of ST-segment elevation myocardial infarction to the catheterization laboratory.

Exclusion criteria

The patients were not considered for enrolment if they presented with unconsciousness, cardiogenic shock, hypoglycaemia, diabetic ketoacidosis, previous myocardial infarction, stent thrombosis, known renal insufficiency, or previous coronary artery bypass operation.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes
2
Cardiometabolic biomarkers
2
Other (unclassified)
1

Cardiovascular outcomes

2 endpoints
Secondary/protocol endpoint

major adverse cardiovascular events (MACE) after 3 months

Time frame:3 months after Primary percutaneous coronary intervention

Expanded / custom MACE composite

composite event, event

componentsMyocardial infarction (any), Unstable angina hospitalization, Coronary revascularization, Heart-failure hospitalization, Cardiovascular death

Secondary/protocol endpoint/low confidence

final infarct size after 3 months

Time frame:3 months after Primary percutaneous coronary intervention

descriptive, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

the levels of high-sensitivity C-reactive protein (hsCRP)

Time frame:3 months after Primary percutaneous coronary intervention

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint/low confidence

nitric oxide (NO) levels

Time frame:3 months after Primary percutaneous coronary intervention

change from baseline, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

the salvage index measured by cardiac magnetic resonance

Time frame:3 months after primary percutaneous coronary intervention

descriptive

Publications (6)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.